عرض بسيط للتسجيلة

المؤلفAl-Nesf, Maryam A. Y.
المؤلفAbdesselem, Houari B.
المؤلفBensmail, Ilham
المؤلفIbrahim, Shahd
المؤلفSaeed, Walaa A. H.
المؤلفMohammed, Sara S. I.
المؤلفRazok, Almurtada
المؤلفAlhussain, Hashim
المؤلفAly, Reham M. A.
المؤلفAl Maslamani, Muna
المؤلفOuararhni, Khalid
المؤلفKhatib, Mohamad Y.
المؤلفHssain, Ali Ait
المؤلفOmrani, Ali S.
المؤلفAl-Kaabi, Saad
المؤلفAl Khal, Abdullatif
المؤلفAl-Thani, Asmaa A.
المؤلفSamsam, Waseem
المؤلفFarooq, Abdulaziz
المؤلفAl-Suwaidi, Jassim
المؤلفAl-Maadheed, Mohammed
المؤلفAl-Siddiqi, Heba H.
المؤلفButler, Alexandra E.
المؤلفDecock, Julie V.
المؤلفMohamed-Ali, Vidya
المؤلفAl-Ejeh, Fares
تاريخ الإتاحة2023-08-28T09:09:49Z
تاريخ النشر2022
اسم المنشورNature Communications
المصدرScopus
الرقم المعياري الدولي للكتاب20411723
معرّف المصادر الموحدhttp://dx.doi.org/10.1038/s41467-022-28639-4
معرّف المصادر الموحدhttp://hdl.handle.net/10576/46831
الملخصCOVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients. 2022, The Author(s).
راعي المشروعThe authors would like to thank all the patients, volunteers, and the healthcare co-workers from Allergy and Immunology Section-HMC, and Dr. Mohamed G.H. Mohamedali, Mr. Hassen Maatoug, and Mr. Ahmed Soliman from Hezm Mebairek General Hospital-HMC for developing disposable racks for samples transportation, tubes labeling, blood collection, and handling. We thank the support provided by Qatar University Biomedical Research Centre, Biosafety Level 3, and Associate Professor Hadi M. Yassine (M.Sc., Ph.D.). We also acknowledge the help of the Anti-Doping Lab-Qatar (ADLQ) and Qatar Red Crescent (QRC) for recruiting control samples. This work was supported by a grant fund from Hamad Medical Corporation (fund number MRC-05-003) and core funding from Qatar Biomedical Research Institute (QBRI).
اللغةen
الناشرNature Research
الموضوعInfection
SARS-CoV-2
Translational immunology
Viral infection
العنوانPrognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications
النوعArticle
رقم العدد1
رقم المجلد13


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة